Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhHGF naked plasmid injection for critical limb ischemia (Rutherford 4)
CTR20190746Phase 3Completed
- Sponsor
- Northland Biotech
- Start
- Apr 2019
- Modality
- Gene Therapies, Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Engensis in chronic limb-threatening ischemia (CLTI), arteriosclerosis obliterans, sponsored by Northland Biotech. Started Apr 2019; status: completed.
02
Drugs
Engensis
03
Conditions
chronic limb-threatening ischemia (CLTI)arteriosclerosis obliterans
Beyond the preview
Go deeper on CTR20190746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190746.